EA201690501A1 - Новые композиции для лечения неврологических расстройств - Google Patents
Новые композиции для лечения неврологических расстройствInfo
- Publication number
- EA201690501A1 EA201690501A1 EA201690501A EA201690501A EA201690501A1 EA 201690501 A1 EA201690501 A1 EA 201690501A1 EA 201690501 A EA201690501 A EA 201690501A EA 201690501 A EA201690501 A EA 201690501A EA 201690501 A1 EA201690501 A1 EA 201690501A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- treatment
- neurological disorders
- new compositions
- alzheimer
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000003130 Alcoholic Neuropathy Diseases 0.000 abstract 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 208000029650 alcohol withdrawal Diseases 0.000 abstract 1
- 208000020701 alcoholic polyneuropathy Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000003492 excitotoxic effect Effects 0.000 abstract 1
- 231100000063 excitotoxicity Toxicity 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Настоящее изобретение относится к композиции и способам для лечения неврологических расстройств, связанных с эксайтотоксичностью глутамата и токсичностью амилоида β. Более конкретно, настоящее изобретение относится к новым комбинированных терапиям рассеянного склероза, болезни Альцгеймера, расстройств, связанных с болезнями Альцгеймера, бокового амиотрофического склероза, болезни Паркинсона, болезни Хантингтона, невропатической боли, алкогольной невропатии, алкоголизма или алкогольной абстиненции или поражения спинного мозга.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/014,650 US9867837B2 (en) | 2011-03-01 | 2013-08-30 | Compositions for treating neurological disorders |
PCT/EP2014/068494 WO2015028659A1 (en) | 2013-08-30 | 2014-09-01 | Composition comprising torasemide and baclofen for treating neurological disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201690501A1 true EA201690501A1 (ru) | 2016-08-31 |
EA034075B1 EA034075B1 (ru) | 2019-12-25 |
Family
ID=51492301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690501A EA034075B1 (ru) | 2013-08-30 | 2014-09-01 | Применение комбинации, содержащей торасемид и баклофен, для регенерации нервов или нейронов и способ, ее использующий |
Country Status (17)
Country | Link |
---|---|
US (3) | US9867837B2 (ru) |
EP (1) | EP3038614B1 (ru) |
JP (1) | JP6395838B2 (ru) |
KR (1) | KR20160067103A (ru) |
CN (1) | CN105744932B (ru) |
AU (1) | AU2014314055B2 (ru) |
BR (1) | BR112016004505A2 (ru) |
CA (1) | CA2922066A1 (ru) |
EA (1) | EA034075B1 (ru) |
ES (1) | ES2733954T3 (ru) |
HK (1) | HK1224182A1 (ru) |
IL (1) | IL244170A0 (ru) |
MX (1) | MX367023B (ru) |
SG (1) | SG11201601312WA (ru) |
UA (1) | UA119445C2 (ru) |
WO (1) | WO2015028659A1 (ru) |
ZA (1) | ZA201601634B (ru) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
US9867837B2 (en) | 2011-03-01 | 2018-01-16 | Pharnext | Compositions for treating neurological disorders |
US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
WO2012117076A2 (en) | 2011-03-01 | 2012-09-07 | Pharnext | Baclofen and acamprosate based therapy of neurogical disorders |
US9931326B2 (en) | 2011-03-29 | 2018-04-03 | Pharnext | Composition comprising torasemide and baclofen for treating neurological disorders |
US9012640B2 (en) * | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
WO2014020608A1 (en) * | 2012-07-31 | 2014-02-06 | Yeda Research And Development Co. Ltd. | Methods of diagnosing and treating motor neuron diseases |
SG11201606275WA (en) | 2014-02-11 | 2016-08-30 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
FR3018688A1 (fr) * | 2014-03-19 | 2015-09-25 | Virbac | Utilisation de torasemide a faible dose dans une composition veterinaire |
NZ729803A (en) * | 2014-10-15 | 2023-07-28 | Orion Corp | A method for the treatment of motor neuron diseases |
KR102364840B1 (ko) | 2014-11-05 | 2022-02-18 | 삼성전자주식회사 | 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법 |
KR101680464B1 (ko) | 2015-04-17 | 2016-11-28 | 가톨릭대학교 산학협력단 | 시나칼셋을 유효성분으로 함유하는 당뇨병성 미세혈관 합병증의 예방 및 치료용 약학적 조성물 |
WO2017083795A1 (en) * | 2015-11-13 | 2017-05-18 | Pietro Paolo Sanna | Methods and compositions for treating alcohol use disorders |
KR101910153B1 (ko) * | 2016-11-04 | 2018-10-19 | 한국과학기술연구원 | 타우 관련 질환의 예방 또는 치료용 레보시멘단 화합물 |
CA3061243C (en) | 2017-04-24 | 2023-02-21 | Pharnext | Idalopirdine-based combinatorial therapies of alzheimer's disease |
EP3638283A1 (en) * | 2017-06-14 | 2020-04-22 | Netzer, Rainer | Antagonists of cav2.3 r-type calcium channels for the treatment of neurodegenerative diseases |
WO2019004321A1 (ja) * | 2017-06-28 | 2019-01-03 | 国立大学法人京都大学 | アルツハイマー病の予防及び/又は治療剤 |
US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
AU2018352236A1 (en) | 2017-10-16 | 2020-04-23 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
CA3088715A1 (en) * | 2018-01-29 | 2019-08-01 | Pharnext | Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy |
EP3755329A4 (en) * | 2018-02-19 | 2021-10-27 | Martin Pharmaceuticals, Inc. | STABLE LIQUID FORMULATION OF TRIMETAZIDINE FOR ORAL USE |
WO2020010035A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Cannula system |
EP3818161A1 (en) | 2018-07-02 | 2021-05-12 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
CN116286669B (zh) * | 2023-03-23 | 2023-09-22 | 江南大学 | 一株分泌托拉塞米单克隆抗体的杂交瘤细胞株及其应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2044853C (en) | 1990-07-19 | 2004-11-09 | Susan A. Greenfield | Method for treating parkinson's disease employing an atp-sensitive potassium channel blocker |
DE4113820A1 (de) | 1991-04-27 | 1992-10-29 | Boehringer Mannheim Gmbh | Verwendung von torasemid zur behandlung von hirnoedemen |
US6294350B1 (en) * | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
US20060025387A1 (en) * | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
US8980952B2 (en) | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
CN101365451A (zh) | 2005-11-21 | 2009-02-11 | 阿拉巴马大学董事会 | 使用小分子化合物用于神经保护的方法 |
US20100056444A1 (en) | 2006-10-12 | 2010-03-04 | Sven Martin Jacobson | Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors |
EP2160408A1 (en) | 2007-06-22 | 2010-03-10 | Bayer Schering Pharma Aktiengesellschaft | Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease |
WO2009033069A1 (en) * | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
PT2282778T (pt) | 2008-04-29 | 2017-04-27 | Pharnext | Novas abordagens terapêuticas no tratamento da doença de alzheimer e doenças relacionadas através de uma modulação da angiogénese |
AU2009242127B2 (en) | 2008-04-29 | 2014-03-27 | Pharnext | New therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of cell stress response |
EA024147B1 (ru) | 2008-04-29 | 2016-08-31 | Фарнекст | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом |
US20100022574A1 (en) * | 2008-07-28 | 2010-01-28 | EndogenX, Inc. | Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist |
CA2750339A1 (en) | 2009-01-22 | 2010-07-29 | Neurotherapeutics Pharma, Inc. | Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use |
EP2263665A1 (en) * | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
US10238622B2 (en) * | 2009-07-24 | 2019-03-26 | Wolfgang S. Mueller | Methods of treating and preventing/reducing the likelihood of Mesial temporal lobe epilepsy (TLE) |
US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
UA113165C2 (xx) * | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
EP2705842A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
US9867837B2 (en) | 2011-03-01 | 2018-01-16 | Pharnext | Compositions for treating neurological disorders |
WO2012117076A2 (en) | 2011-03-01 | 2012-09-07 | Pharnext | Baclofen and acamprosate based therapy of neurogical disorders |
US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
US9931326B2 (en) | 2011-03-29 | 2018-04-03 | Pharnext | Composition comprising torasemide and baclofen for treating neurological disorders |
US9700037B1 (en) | 2014-09-08 | 2017-07-11 | Justin P. Chatelain | Duck decoy device |
US9700036B1 (en) | 2015-04-08 | 2017-07-11 | Justin P. Chatelain | Duck decoy device |
-
2013
- 2013-08-30 US US14/014,650 patent/US9867837B2/en not_active Expired - Fee Related
-
2014
- 2014-01-09 UA UAA201603187A patent/UA119445C2/uk unknown
- 2014-09-01 BR BR112016004505A patent/BR112016004505A2/pt not_active IP Right Cessation
- 2014-09-01 MX MX2016002644A patent/MX367023B/es active IP Right Grant
- 2014-09-01 EP EP14759137.4A patent/EP3038614B1/en not_active Not-in-force
- 2014-09-01 KR KR1020167008433A patent/KR20160067103A/ko not_active Application Discontinuation
- 2014-09-01 SG SG11201601312WA patent/SG11201601312WA/en unknown
- 2014-09-01 WO PCT/EP2014/068494 patent/WO2015028659A1/en active Application Filing
- 2014-09-01 ES ES14759137T patent/ES2733954T3/es active Active
- 2014-09-01 EA EA201690501A patent/EA034075B1/ru not_active IP Right Cessation
- 2014-09-01 CA CA2922066A patent/CA2922066A1/en not_active Abandoned
- 2014-09-01 CN CN201480047851.XA patent/CN105744932B/zh not_active Expired - Fee Related
- 2014-09-01 JP JP2016537324A patent/JP6395838B2/ja not_active Expired - Fee Related
- 2014-09-01 AU AU2014314055A patent/AU2014314055B2/en not_active Ceased
-
2016
- 2016-02-17 IL IL244170A patent/IL244170A0/en unknown
- 2016-03-09 ZA ZA2016/01634A patent/ZA201601634B/en unknown
- 2016-10-27 HK HK16112419.0A patent/HK1224182A1/zh not_active IP Right Cessation
-
2017
- 2017-12-20 US US15/848,230 patent/US20180125867A1/en not_active Abandoned
-
2018
- 2018-07-02 US US16/025,461 patent/US10434109B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2016529274A (ja) | 2016-09-23 |
BR112016004505A2 (pt) | 2017-09-12 |
CA2922066A1 (en) | 2015-03-05 |
US9867837B2 (en) | 2018-01-16 |
KR20160067103A (ko) | 2016-06-13 |
WO2015028659A1 (en) | 2015-03-05 |
CN105744932A (zh) | 2016-07-06 |
EP3038614A1 (en) | 2016-07-06 |
UA119445C2 (uk) | 2019-06-25 |
HK1224182A1 (zh) | 2017-08-18 |
US20180125867A1 (en) | 2018-05-10 |
ZA201601634B (en) | 2017-08-30 |
US20180338988A1 (en) | 2018-11-29 |
AU2014314055A1 (en) | 2016-03-10 |
EA034075B1 (ru) | 2019-12-25 |
EP3038614B1 (en) | 2019-04-03 |
ES2733954T3 (es) | 2019-12-03 |
JP6395838B2 (ja) | 2018-09-26 |
SG11201601312WA (en) | 2016-03-30 |
US20140038927A1 (en) | 2014-02-06 |
MX2016002644A (es) | 2016-10-04 |
IL244170A0 (en) | 2016-04-21 |
US10434109B2 (en) | 2019-10-08 |
CN105744932B (zh) | 2019-01-08 |
AU2014314055B2 (en) | 2019-11-21 |
MX367023B (es) | 2019-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690501A1 (ru) | Новые композиции для лечения неврологических расстройств | |
CY1120369T1 (el) | Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης | |
EA201300975A1 (ru) | Новые композиции для лечения неврологических заболеваний | |
HK1258231A1 (zh) | 治療阿爾茨海默氏症、亨廷頓氏症、孤獨症和其他障礙的方法 | |
CR20180452A (es) | Moduladores alostéricos de receptores de acetilcolina nicotícos | |
MX2016002238A (es) | Alcoholes de alquilino y metodos de uso. | |
MX2016002241A (es) | Alcoholes de alquinilo y metodos de uso. | |
MX2014014902A (es) | Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas. | |
EA201691514A1 (ru) | Соединения | |
WO2015011284A3 (en) | Inhibitors of fapp2 and uses thereof | |
CR20160394A (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
WO2014160871A8 (en) | Methods and agents for treating alzheimer's disease | |
WO2014145485A3 (en) | Map kinase modulators and uses thereof | |
NZ709399A (en) | Method of treatment of hypoxia inducible factor (hif)-related conditions | |
MX2018000202A (es) | Analogos de cisteamina resistentes a la ado y sus usos. | |
MX2016000724A (es) | Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. | |
WO2016059269A8 (es) | Compuestos derivados de acrilato de 3-alouilamino-1h- indolilo y su uso en el tratamiento de enfermedades neurodegenerativas | |
BR112016016098A2 (pt) | Compostos orgânicos | |
AU2019268209A1 (en) | Compounds for the treatment of seizures and other central nervous system disorders and conditions | |
MY174744A (en) | Uses of bacopa monnieri extract | |
EA201792076A1 (ru) | Методы и композиции для внутривенного введения фумаратов для лечения неврологических заболеваний | |
WO2014111525A3 (en) | Combination therapies for treating nervous system diseases | |
DOP2014000179A (es) | Agonistas de mglu 2/3 | |
EA201401142A1 (ru) | Замещенные 6-аминоникотинамиды, несущие он-содержащую группу, в качестве модуляторов kcnq2/3 | |
ECSP14012098A (es) | Agonistas de mglu 2/3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |